A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Single Intravenous Dose, Ascending Dose Level Study of the Safety, Tolerability and Pharmacokinetics of GLYX-13 in Normal Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Rapastinel (Primary) ; Rapastinel (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Naurex
  • Most Recent Events

    • 26 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 26 May 2015 Planned End Date changed from 1 Feb 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top